Clinical trials: Covid-19 Pneumonia
COVID-19
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan
This is an observational, cohort study that will use secondary data to describe the baseline demographics and clinical characteristics in patients who received EVUSHELD as PrEP against SARS-CoV-2 infection/COVID-19 in Japan.
- Trial name
- Evusheld DBR (NCT06156982)
- Testing
- Evusheld
- Where
- Japan
- Volunteers
- 397 people
- Sponsor
- AstraZeneca
COVID-19 Pneumonia
Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.
This was a randomized, double-blind, placebo-controlled parallel study.
- Trial name
- NCT05672888
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
ARDS
Ventilatory Efficiency in Critically Ill COVID-19 Patients
The new severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2) causes the illness named COVID-19, which is primarily characterized by pneumonia.
- Trial name
- NCT04694742
- Testing
- data collecting
- Where
- 4 sites in Italy
- Volunteers
- 100 people
- Sponsor
- ASST Fatebenefratelli Sacco
Bladder Cancer, Covid19
The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations
In this study, investigators aim to reveal how the COVID-19 pandemic process affects primary bladder cancer presentations, tumor stages and degrees, the time elapsed between diagnosis and intervention, tumor recurrence and…
- Trial name
- NCT04900259
- Testing
- COVID-19 pandemic
- Where
- Turkey (Türkiye)
- Volunteers
- 183 people
- Sponsor
- Ankara Training and Research Hospital
Covid19
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
Ivermectin, a classical antiparasitic and anti-scabies agent, has demonstrated antiviral activity for a variety of viruses including chikungunya virus, zyka virus and dengue virus and was tested as a potentially effective for…
- Trial name
- NCT04712279
- Testing
- Ivermectin 0.6mg/kg/day, Ivermectin 1.0mg/kg/day, Hydroxychloroquine
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Corpometria Institute
COVID-19, HIV Infections
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected
Evaluation of immunogenicity and safety of the subjects infected with HIV to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .
- Trial name
- NCT05075070
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
COVID-19, Vitamin D Deficiency
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
The purpose of this study is to evaluate how useful vitamin D supplementation is in reducing the severity of COVID-19 symptoms and the body's inflammatory and infection-fighting response to COVID-19.
- Conditions
- COVID-19, Vitamin D Deficiency, Respiratory Viral Infection
- Trial name
- VitD-COVID19 (NCT04482673)
- Testing
- Daily Vitamin D3, Bolus vitamin D3
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Covid19
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization.
- Trial name
- COPPS (NCT04662073)
- Testing
- Camostat
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Covid19
Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt
Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis.
- Trial name
- NCT04773756
- Testing
- Sofosbuvir 400 MG/ Daclatasvir 60mg
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Alexandria University
COVID-19
Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial
Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), a new corona virus that emerged in Wuhan, China, in December 2019.
- Trial name
- NCT05930002
- Testing
- Ivermectin Tablets, Colchicine 0.5 MG, Standared managment
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
COVID-19
The Impact of Statin Therapy in the Covid-19 Patients
In the retrospective case series, consecutive COVID-19 patients admitted from June 1 to December 31, 2020, were analyzed. A 1:1 matched cohort was created by propensity score-matched analysis.
- Trial name
- NCT05238402
- Testing
- Statin
- Where
- Turkey (Türkiye)
- Volunteers
- 707 people
- Sponsor
- Antalya Training and Research Hospital
COVID-19
Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia
At present, no treatment has been approved for COVID-19. However, in light of the increased interest on using the anti-cytokine therapy targeting IL-6 tocilizumab in COVID-19 infected patients due to its potential benefit, the…
- Trial name
- NCT04445272
- Testing
- Tocilizumab
- Where
- 42 sites in Spain
- Volunteers
- 495 people
- Sponsor
- Fundacion SEIMC-GESIDA
Adverse Drug Event
Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers
Limited large-scale studies have been conducted to investigate the adverse effects of COVID-19 vaccine in Latin America, particularly among the healthcare worker (HCW) population in Ecuador.
- Trial name
- NCT05113472
- Testing
- Pfizer-BioNTech COVID-19 vaccine
- Where
- Ecuador
- Volunteers
- 1,291 people, healthy volunteers welcome
- Sponsor
- Respiralab
Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who received first COVID-19…
- Conditions
- Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19
- Trial name
- NCT05803395
- Where
- 15 sites in Italy
- Volunteers
- 954 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Post Acute COVID 19 Syndrome, Memory Impairment
HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)
The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Post Acute Covid Syndrome (PACS).
- Conditions
- Post Acute COVID 19 Syndrome, Memory Impairment, Memory Dysfunction, Cognitive Dysfunction
- Trial name
- NCT06391489
- Testing
- HOBSCOTCH-PACS
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Covid19, Athletes Heart
Effect of CoVid-19 (CoronaVirusDisease-19) and Exercise on Myocardial Fibrosis and Ventricular Arrhythmias
COVID-19 can cause myocarditis, which can cause myocardial fibrosis. This has been shown to increase mortality and morbidity among athletes.
- Conditions
- Covid19, Athletes Heart, Myocarditis Viral, Ventricular Arrythmia
- Trial name
- CoViDEx (NCT04726150)
- Testing
- ILR implantation
- Where
- Belgium
- Volunteers
- 85 people
- Sponsor
- University Hospital, Antwerp
COVID-19, Virus Disease
Prevalence of Myocardial Scars on CMR After COVID-19 Infection
The aim of this study is to assess the prevalence and arrhythmogenic role of occult myocardial scars on Cardiac Magnetic Resonance (CMR) in a population of patients with history of laboratory-proven symptomatic COVID-19 infection…
- Trial name
- COVID-CMR (NCT04636320)
- Testing
- Contrast-enhanced CMR, Exercise test ECG, Blood sample
- Where
- France
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Long COVID
Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID.
- Trial name
- NCT06437223
- Testing
- Tonabersat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Inflammx Therapeutics Inc
COVID-19, SARS-CoV-2
Study of Sargramostim in Patients With COVID-19
The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19.
- Trial name
- iLeukPulm (NCT04411680)
- Testing
- Sargramostim, Standard of care
- Where
- 11 sites in United States
- Volunteers
- 123 people
- Sponsor
- Partner Therapeutics, Inc.
Injuries
Has The COVID-19 Pandemic Affected Injury in Football?
This study aims to compare the injuries that occurred in the football players after the isolation and lack of training caused by New Coronavirus Disease (COVID-19), with the previous season, based on the example of a professional…
- Trial name
- NCT05262283
- Testing
- No intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Karadeniz Technical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.